Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Top Cited Papers
- 15 July 2004
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 114 (2) , 280-290
- https://doi.org/10.1172/jci200421583
Abstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO). Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs. Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19. We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Keywords
This publication has 61 references indexed in Scilit:
- Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T CellsThe Journal of Experimental Medicine, 2003
- Increasing Tumor Antigen Expression Overcomes “Ignorance” to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal CellsImmunity, 2002
- Regulation of tumour immunity by CD25+ T cellsImmunology, 2002
- Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without ToleranceThe Journal of Experimental Medicine, 2002
- Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progressionBlood, 2001
- T cells and tumoursNature, 2001
- Roles of tumour localization, second signals and cross priming in cytotoxic T-cell inductionNature, 2001
- A fresh look at tumor immunosurveillance and immunotherapyNature Immunology, 2001
- Induction of antigen-specific T cell anergy: An early event in the course of tumor progressionProceedings of the National Academy of Sciences, 1998
- Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic AnergyThe Journal of Experimental Medicine, 1997